After spending six figures on fertility treatment across five cycles, three clinics, and two countries, Nader AlSalim built Gaia around a problem he knew personally: patients often pay again and again even when treatment fails. Now the New York-based fertility startup has secured a $100 million debt facility from Viola Credit to expand its outcome-based financing model across the United States. Gaia uses AI and machine learning to forecast fertility treatment outcomes and create plans that include financial protection for IVF, egg freezing, and embryo transfers.
The platform analyzes patient variables such as age, hormone levels, ovarian response, treatment protocols, embryo development, and clinical outcomes to forecast fertility success and connect patients with clinics suited to their profiles. For an IVF cycle, which has a nationwide median cost of $22,000, Gaia says it will fund another cycle at no extra cost if the first one fails. For embryo transfers, the plan includes unlimited transfers until a live birth occurs.
The credit facility follows a $14 million Series A round raised in January 2025 led by Valar Ventures, bringing Gaia’s total equity funding to $37 million. The company’s other backers include Atomico and Kindred Capital. Venture investment in fertility startups remains relatively niche, with global funding in Crunchbase’s fertility categories ranging between roughly $100 million and $200 million annually since its 2021 peak.
Gaia has surpassed 1,100 memberships and works with 200 clinic locations across 40 states. The company has expanded beyond direct-to-consumer marketing through clinic partnerships, pharmaceutical relationships, and an enterprise benefits product for employers. AlSalim told Crunchbase News that Gaia is “not just a financing company,” adding that it uses data to create individualized plans with outcome protections built in.
